Physiologically‐based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population

• Main Authors: Elizabeth J. Thompson (Author), Angela Jeong (Author), Victória E. Helfer (Author), Valentina Shakhnovich (Author), Andrea Edginton (Author), Stephen J. Balevic (Author), Laura P. James (Author), David N. Collier (Author), Ravinder Anand (Author), Daniel Gonzalez (Author), the Best Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee (Author)
• Format: Book
• Published: Wiley, 2024-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Pantoprazole is a proton pump inhibitor indicated for the treatment of gastroesophageal reflux disease, a condition that disproportionately affects children with obesity. Appropriately dosing pantoprazole in children with obesity requires understanding the body size metric that best guides...